PRABITAS study

INTERVENTION: Group A: Conventional FTD/TPI+BEV 1 cycle of 28 days FTD/TPI: 35mg/m2/dose, administered orally BID, day 1‐5, 8‐12 (day 2‐6, 9‐13) BEV: 5mg/kg, administered IV on day 1 and 15. Group B: Bi‐weekly FTD/TPI+BEV FTD/TPI: 35mg/m2/dose, administered orally BID, day 1‐5 (day 2‐6) BEV: 5mg/kg, administered IV on day 1 CONDITION: colorectal cancer PRIMARY OUTCOME: Overall survival:OS SECONDARY OUTCOME: Progression free survival: PFS; Response rate: RR; Disease control rate: DCR; Time to treatment failure: TTF ; Safety INCLUSION CRITERIA: 1) Histopathologically diagnosed as adenocarcinoma of the colon. 2) Diagnosed as metastatic colorectal cancer. 3) Age 18 years or older on the date of consent. 4) ECOG PS of 0‐2. 5) Confirmed RAS gene status by tumor tissue. 6) Received all fluoropyrimidines, oxaliplatin, irinotecan and molecular targeted agents. 7) No previous administration of FTD/TPI. 8) Ability to safely receive the protocol treatment. 9) Written informed consent obtained from the patient.